Z. Erjavec

3.7k total citations · 1 hit paper
24 papers, 2.5k citations indexed

About

Z. Erjavec is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Z. Erjavec has authored 24 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Infectious Diseases. Recurrent topics in Z. Erjavec's work include Neutropenia and Cancer Infections (7 papers), Antifungal resistance and susceptibility (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Z. Erjavec is often cited by papers focused on Neutropenia and Cancer Infections (7 papers), Antifungal resistance and susceptibility (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Z. Erjavec collaborates with scholars based in Netherlands, Iran and France. Z. Erjavec's co-authors include Ben de Pauw, Jacques F. Meis, J. Ritter, F. Crokaert, Thomas F. Patterson, John Rex, D Fière, David W. Denning, John E. Bennett and Johan Maertens and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

Z. Erjavec

23 papers receiving 2.5k citations

Hit Papers

Defining Opportunistic Invasive Fungal Infections in Immu... 2002 2026 2010 2018 2002 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
    2002 1.9k citations John Rex, Ben de Pauw et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Z. Erjavec Netherlands 16 1.9k 1.8k 648 377 293 24 2.5k
Stephen Dummer United States 19 1.7k 0.9× 1.8k 1.0× 632 1.0× 321 0.9× 260 0.9× 30 2.6k
Werner Heinz Germany 34 2.7k 1.5× 2.6k 1.5× 783 1.2× 294 0.8× 372 1.3× 91 3.5k
Harrys A. Torres United States 35 1.7k 0.9× 2.4k 1.3× 586 0.9× 199 0.5× 271 0.9× 114 3.6k
J. Hiemenz United States 13 1.4k 0.8× 1.3k 0.7× 398 0.6× 180 0.5× 278 0.9× 23 2.0k
Angelika Böhme Germany 23 1.3k 0.7× 1.2k 0.7× 617 1.0× 140 0.4× 210 0.7× 59 1.8k
Pietro Martino Italy 22 1.3k 0.7× 1.3k 0.8× 789 1.2× 157 0.4× 168 0.6× 42 2.3k
J Tollemar Sweden 30 1.7k 0.9× 1.7k 1.0× 463 0.7× 218 0.6× 177 0.6× 87 3.1k
V. A. Morrison United States 14 1.2k 0.7× 1.0k 0.6× 291 0.4× 216 0.6× 212 0.7× 26 1.9k
Ben de Pauw Netherlands 21 2.6k 1.4× 2.5k 1.4× 1.1k 1.7× 479 1.3× 366 1.2× 41 4.0k
John W. Hiemenz United States 14 1.4k 0.7× 1.3k 0.7× 322 0.5× 156 0.4× 293 1.0× 28 2.0k

Countries citing papers authored by Z. Erjavec

Since Specialization
Citations

This map shows the geographic impact of Z. Erjavec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Z. Erjavec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Z. Erjavec more than expected).

Fields of papers citing papers by Z. Erjavec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Z. Erjavec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Z. Erjavec. The network helps show where Z. Erjavec may publish in the future.

Co-authorship network of co-authors of Z. Erjavec

This figure shows the co-authorship network connecting the top 25 collaborators of Z. Erjavec. A scholar is included among the top collaborators of Z. Erjavec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Z. Erjavec. Z. Erjavec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kroep, Judith R., Erik van Werkhoven, Marco B. Polée, et al.. (2015). Randomised study of tegafur–uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer — TLC study. Journal of Geriatric Oncology. 6(4). 307–315. 15 indexed citations
2.
Schaafsma, Martyn Ronald, Peter Joosten, E.F.M. Posthuma, et al.. (2015). Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Quality of Life Research. 24(12). 2895–2906. 36 indexed citations
3.
Meulenbeld, Hielke J., Jeanine M.L. Roodhart, Ankie M.T. van der Velden, et al.. (2013). Analysis of docetaxel therapy in elderly (⩾70years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. European Journal of Cancer. 49(15). 3176–3183. 24 indexed citations
4.
Schaafsma, M. Ronald, Okke de Weerdt, Peter Joosten, et al.. (2013). Real-world costs of chronic lymphocytic leukaemia in the Netherlands. Leukemia Research. 38(1). 84–90. 8 indexed citations
5.
6.
Schröder, Carolien P., Linda de Munck, Anneke M. Westermann, et al.. (2011). Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel. European Journal of Cancer. 47(9). 1355–1362. 26 indexed citations
7.
Erjavec, Z., Hanneke C. Kluin‐Nelemans, & Paul E. Verweij. (2009). Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clinical Microbiology and Infection. 15(7). 625–633. 71 indexed citations
8.
Munck, Linda de, G.J. Creemers, H. de Graaf, et al.. (2007). A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 106. 1 indexed citations
9.
Harteveld, Cornelis L., Marjolein Kriek, Emilia K. Bijlsma, et al.. (2007). Refinement of the genetic cause of ATR-16. Human Genetics. 122(3-4). 283–292. 19 indexed citations
10.
Hospers, Geke A.P., Michael Schaapveld, J.W.R. Nortier, et al.. (2006). Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Annals of Oncology. 17(3). 443–449. 29 indexed citations
11.
Wachters, Floris M, J.W.G. van Putten, Henk Kramer, et al.. (2003). First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. British Journal of Cancer. 89(7). 1192–1199. 53 indexed citations
12.
Rex, John, Ben de Pauw, John E. Bennett, et al.. (2002). Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. Clinical Infectious Diseases. 34(1). 7–14. 1889 indexed citations breakdown →
13.
Harteveld, Cornelis L., et al.. (2002). Hb DELFZICHT [α9(A7)Asn→Lys (α1)]: A NEW, CLINICALLY SILENT HEMOGLOBIN VARIANT OBSERVED IN A DUTCH PATIENT. Hemoglobin. 26(2). 181–184. 1 indexed citations
14.
Erjavec, Z. & Paul E. Verweij. (2002). Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resistance Updates. 5(1). 3–10. 31 indexed citations
15.
Erjavec, Z., et al.. (2000). Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer. 82(4). 806–811. 1 indexed citations
16.
Janknegt, R., et al.. (2000). Antibiotics in granulocytopenic patients with fever. Drug selection by means of the SOJA method.. 3(2). 1 indexed citations
17.
18.
Putten, J.W.G. van, et al.. (2000). Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study. British Journal of Cancer. 82(4). 806–811. 19 indexed citations
19.
Erjavec, Z., et al.. (1997). Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. European Journal of Clinical Microbiology & Infectious Diseases. 16(5). 364–368. 59 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen Dummer Breakdown of academic impact, for papers by Werner Heinz Breakdown of academic impact, for papers by Harrys A. Torres Breakdown of academic impact, for papers by J. Hiemenz Breakdown of academic impact, for papers by Angelika Böhme Breakdown of academic impact, for papers by Pietro Martino Breakdown of academic impact, for papers by J Tollemar Breakdown of academic impact, for papers by V. A. Morrison Breakdown of academic impact, for papers by Ben de Pauw Breakdown of academic impact, for papers by John W. Hiemenz
Rankless by CCL
2026